# F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

> **NCT00602043** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (actual)

## Conditions studied

- Estrogen Receptor-positive Breast Cancer
- Progesterone Receptor-negative Breast Cancer
- Progesterone Receptor-positive Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **RADIATION:** F-18 16 alpha-fluoroestradiol
- **RADIATION:** fludeoxyglucose F 18
- **PROCEDURE:** positron emission tomography
- **PROCEDURE:** positron emission tomography
- **PROCEDURE:** computed tomography
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00602043
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-08
- **Final completion:** 2014-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602043, "F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00602043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*